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background:  Cholesterol contained within triglyceride-rich lipoprotein particles is believed to be atherogenic. It can be calculated as remnant 
cholesterol = total cholesterol - [HDL-C + LDL-C]. We examined the relationship between remnant cholesterol and residual risk after acute coronary 
syndrome (ACS). 
methods: The dal-Outcomes trial compared the CETP inhibitor dalcetrapib with placebo in patients with recent ACS. Remnant cholesterol was 
calculated at baseline (4-12 weeks after ACS) in 15,817 participants, 97% of whom were treated with statins with mean LDL-C 76 mg/dl. The 
primary outcome was a composite of coronary heart disease death, non-fatal myocardial infarction, ischemic stroke, hospitalization for unstable 
angina, or resuscitated cardiac arrest. Median followup was 31 months. 
results: A strong, graded relationship between remnant cholesterol and risk of a primary outcome was found in univariate analysis (P for trend 
<.001). The relationship persisted after adjustment for age, sex, hypertension, smoking, and diabetes (Figure), in patients with LDL-C above or below 
mean (interaction P=0.91), in both placebo and dalcetrapib groups, and when LDL-C was measured directly or calculated with Friedewald formula. 
Conclusions: In a contemporary ACS population well-treated with statins, residual risk is strongly related to levels of remnant cholesterol. Remnant 
cholesterol may be an important target for additional therapy. 
